BioLineRx (BLRX) Cash & Equivalents (2012 - 2025)

BioLineRx's Cash & Equivalents history runs 14 years deep, the most recent figure standing at $3.2 million for Q4 2025.

• In Q4 2025, Cash & Equivalents fell 68.86% year-over-year to $3.2 million; the TTM figure through Dec 2025 stood at $3.2 million (down 68.86% YoY), while the FY2025 annual figure was $3.2 million, down 68.86% from the prior year.
• Cash & Equivalents was $3.2 million for Q4 2025 at BioLineRx, down from $7.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $17.5 million in Q2 2021 to a low of $3.2 million in Q4 2025.
• Historically, Cash & Equivalents has averaged $10.1 million across 5 years, with a median of $10.4 million in 2024.
• The sharpest annual moves came in 2021 and 2025: Cash & Equivalents jumped 230.07% in 2021, then plunged 68.86% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $13.0 million in 2021, then dropped by 18.5% to $10.6 million in 2022, then slumped by 59.81% to $4.3 million in 2023, then soared by 145.26% to $10.4 million in 2024, then slumped by 68.86% to $3.2 million in 2025.
• The last three Cash & Equivalents figures came in at $3.2 million (Q4 2025), $7.9 million (Q3 2025), and $10.4 million (Q2 2025), per Business Quant data.